federal regulators canceled a meeting around the company's
    experimental drug to treat a debilitating liver condition.

    The delayed meeting with the Food and Drug Administration 
    essentially let loose a domino action: The company's future
    clinical trial plans are set back and it must find ways to
    reduce its cash burn in the meantime.